Phascolarctobacterium

Most gut bacteria that get attention make something. This one eats something. Phascolarctobacterium consumes succinate, a metabolic leftover that other gut microbes produce and that builds up in an inflamed colon, and converts it mainly into propionate, with some species also releasing acetate. Both are short-chain fats your intestinal lining runs on.

That job is why its abundance keeps showing up in studies of body weight, insulin sensitivity, and colonic inflammation. This is a research-grade measurement without standardized clinical cutoffs, so treat your number as a data point in a pattern, not a verdict.

What the Test Actually Measures

The assay detects bacterial DNA in your stool using PCR, a lab technique that copies a specific stretch of genetic material until there is enough to count. Most published research on this organism uses a related approach called 16S rRNA sequencing, which reads a barcode region of bacterial DNA to identify who is present. The two methods are close cousins but not identical, so exact numbers do not transfer cleanly between labs.

Results are reported as relative abundance: what share of the total bacterial signal in your sample belongs to this genus. That framing matters. If another group blooms, your Phascolarctobacterium share can fall without the organism itself changing at all.

Two species dominate the literature: Phascolarctobacterium faecium and Phascolarctobacterium succinatutens. Most panels report at the genus level, which lumps them together. The strongest metabolic evidence is specifically about P. faecium, so a genus-level result is a rough proxy for the species that has been studied most.

Body Weight and Insulin Sensitivity

The clearest human signal is metabolic. A pooled analysis of 7,569 human stool metagenomes found P. faecium was 16% less likely to be detected in people who were overweight and 19% less likely in people with obesity, compared with people at normal weight. Those are detection rates across a large, multi-cohort population, not a personal risk score.

A separate study went further than body weight. In overweight and obese adults measured with a hyperinsulinemic-euglycemic clamp, the most precise way to quantify how well the body responds to insulin, higher fecal Phascolarctobacterium tracked with better insulin sensitivity. That is a correlation in a small study, but it points at the same place the weight data does.

The mechanism has been tested, though only in mice. Giving P. faecium to mice on a high-calorie diet shifted their immune cells toward a repair-oriented state, reduced body fat, and reversed glucose intolerance. That is animal work. It makes the human correlations more believable, but it does not establish that raising this organism in your gut will change your metabolism.

Intestinal Inflammation

When the colon is inflamed, this organism tends to disappear. It is significantly depleted in ulcerative colitis and in people with primary sclerosing cholangitis alongside inflammatory bowel disease, a bile duct condition that often travels with IBD. Lower abundance also tracks with lower blood levels of markers that reflect bacterial products leaking from the gut into circulation.

There is a plausible loop here. Succinate accumulates in inflamed intestinal tissue. Phascolarctobacterium is one of the two main organisms that clear it. Researchers have started sorting gut communities by which succinate-eater dominates, Phascolarctobacterium or Dialister, and that split itself associates with inflammatory bowel disease status in a large cross-sectional dataset.

Depletion also shows up after gallbladder removal in people who develop chronic diarrhea afterward, alongside altered bile acid chemistry, and it tracks with progression of chronic hepatitis B. Lower levels predicted more recurrences of confusion caused by liver failure in people with cirrhosis. None of this is diagnostic on its own.

Where High Levels Show Up, and Why That Isn't a Contradiction

Here is the part that trips people up. If lower is worse in obesity and colitis, higher should be better everywhere. It isn't. Elevated Phascolarctobacterium has been reported in subsets of major depressive disorder, in meta-analyses of Alzheimer's disease, in children with autism and constipation alongside high fecal propionate, and in chronic fatigue syndrome.

The resolution is that this is not a good-number/bad-number marker. It is an indicator of what your colon is fermenting and how fast things move through it. Slower transit and a succinate-rich environment both favor this organism, and both also happen in conditions that have nothing to do with metabolism. A high reading in someone with chronic constipation means something different from a high reading in a lean, regular person. The number describes an ecosystem state; the clinical meaning depends entirely on which state you are in.

Two genetic analyses using inherited variation to probe cause, rather than correlation, point in opposite directions: one links higher gut Phascolarctobacterium to lower periodontal disease and mouth ulcer risk, another to higher benign prostatic hyperplasia risk, and the second result was unstable across sensitivity checks. Read both as hypothesis-generating.

Cancer Treatment Response

Two oncology cohorts found this organism enriched in people whose treatment worked. In advanced non-small cell lung cancer treated with immune checkpoint drugs, high relative abundance appeared in 67% of people with clinical benefit and tracked with longer progression-free survival. In a cohort of 76 women with ovarian cancer on PARP inhibitors, high abundance tracked with longer progression-free survival among those without BRCA1/2 mutations.

These are small, single-purpose cohorts. They do not make this a test to order before starting cancer therapy. They do suggest the same colonic fermentation state that shows up in metabolic health also travels with a more responsive immune environment.

Why a Single Reading Can Fool You

Start with variability, because it is the biggest problem. A single spot stool sample captures one moment in a system that shifts with what you ate over the last few days, how fast things moved through your colon, and where in the stool the swab landed. Gut communities show marked short-term swings after diet changes before settling back toward an individual baseline.

• Relative abundance is a share, not a count: if another genus expands, your percentage drops even when nothing happened to this organism. Look at the whole panel, not one line.
• Recent antibiotics: any course in the preceding weeks scrambles the community and makes a single reading unrepresentative of your usual state.
• Acute diarrheal illness: stool sampled during or shortly after an infection reflects a disrupted system, not your baseline. Wait several weeks.
• Method differences between labs: PCR and 16S sequencing report different numbers for the same sample, so do not compare a result from one provider against a reference from another.

Two medications have documented effects worth knowing. Dual antiplatelet therapy with aspirin and clopidogrel significantly depletes this genus. Proton pump inhibitors reshape the gut community by letting mouth bacteria survive the stomach and colonize downstream. If you are on either, your reading reflects the drug as much as your underlying biology.

Tracking Your Trend

Because a single sample carries so much noise, one number tells you very little. What tells you something is a direction across several samples taken under similar conditions: same collection kit, same general diet, no recent antibiotics, no acute illness.

Get a baseline now. If you are changing your diet or trying a fiber or probiotic intervention, retest at 3 months, which is long enough for a real shift to show and short enough to connect the change to what you did. After that, annually is a reasonable cadence for tracking whether your gut ecology is drifting. Anyone managing an inflammatory bowel condition or actively working on metabolic health has more reason to retest on the shorter end.

When you retest, hold conditions as constant as you can. A big diet change between samples makes the comparison uninterpretable. So does a course of antibiotics. Note both in your own records so a future reading does not confuse you.

What to Do With an Unexpected Result

Do not act on this line alone. Read it against the rest of your stool panel first. Very low abundance alongside low Faecalibacterium prausnitzii, low total short-chain fatty acids, and elevated calprotectin describes a colon under inflammatory stress, and calprotectin is the number that should drive your next move, not this one. Very low abundance in an otherwise unremarkable panel is noise until a repeat sample says otherwise.

If a low reading sits alongside real symptoms, persistent diarrhea, blood in stool, unexplained weight loss, or worsening abdominal pain, the workup you need is a gastroenterology evaluation with fecal calprotectin and, depending on findings, colonoscopy. A commensal bacterial abundance never substitutes for that pathway.

If your number sits low and your metabolic markers are also drifting, higher fasting insulin, rising HbA1c, rising triglycerides, that combination is worth taking more seriously than either finding alone. The action there is metabolic, driven by the blood markers. Treat this reading as supporting context, not as the thing to fix.